Belotero Revive
Belotero Revive (HA + glycerol skin booster)
A skin booster (Belotero Revive) combining hyaluronic acid (HA) with glycerol, used to improve hydration, radiance and fine lines in skin showing early signs of sun damage.
What is it?
Belotero Revive is an injectable that combines hyaluronic acid with glycerol, a moisturizing ingredient. The HA draws water into the skin to fill it, while the glycerol holds on to that moisture so hydration lasts longer. Micro-injected into the dermis, it improves skin hydration, elasticity and fine lines. It was developed to improve skin quality in early photoaging caused by UV exposure and similar factors.
Who it's for
- Fine lines and rough texture from early photoaging (sun-related aging)
- Dry, dehydrated skin; dullness and loss of glow
- Early stages of declining skin elasticity
- Dewy glow and smoothness improve over several weeks
At Datena
1cc = both butterfly zones / 2cc = full face, focusing on the butterfly zones
Before treatment
- We'll let you know about a higher chance of bruising if you take blood thinners or aspirin
- Postponed if there's inflammation or infection in the treatment area
- Treatment is generally deferred during pregnancy or breastfeeding
After treatment
- Avoid saunas, alcohol and intense exercise for a few days
- Step up moisturizing and sun protection
Good to know
- Injection marks and small bumps: usually absorbed within a few days
- Bruising, swelling, redness: improve within a few days
- Rarely, infection or hypersensitivity reactions
- As an HA product, it can be dissolved with hyaluronidase if any problem arises
"An upgrade to the glass-skin booster — an injection that fills moisture in + locks it there" "A great fit for early aging, when fine lines are just starting" "A product used in Europe to improve photoaging" "A natural, dewy glow — skin that looks better without looking 'done'"
Results and recovery time vary depending on your skin. Pricing and the exact number of sessions will be explained during your consultation after diagnosis. Written based on in-clinic materials as of October 2026.
